Bessemer Group’s Enliven Therapeutics ELVN Stock Holding History

Bessemer Group’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-45	Closed	-$1K	–	2511
2024 Q3	$1K	Buy	+45	New	+$1.04K	﹤0.01%	2390

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Bessemer Group's ELVN Position: Q4 2024 in Review

Bessemer Group sold out of Enliven Therapeutics (ELVN) in Q4 2024, closing a stake of 45 shares — an estimated $1K sold.

Bessemer Group first reported a position in ELVN in Q3 2024 and held it in 1 quarter. The position peaked at $1K in Q3 2024. 113 funds tracked by Wall St. Rank hold ELVN as of Q4 2024.

Bessemer Group reported no remaining Enliven Therapeutics position as of Q4 2024 after selling out during the quarter.
Bessemer Group sold 45 Enliven Therapeutics shares in Q4 2024, an estimated $1K.
Bessemer Group first reported a position in Enliven Therapeutics in Q3 2024 and held it in 1 quarter.
Bessemer Group's Enliven Therapeutics position peaked at $1K in Q3 2024.
113 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.